Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Viracta Therapeutics Inc (VIRX)

Viracta Therapeutics Inc (VIRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,388
  • Shares Outstanding, K 5,174
  • Annual Sales, $ 120 K
  • Annual Income, $ -21,610 K
  • 60-Month Beta 2.38
  • Price/Sales 346.19
  • Price/Cash Flow N/A
  • Price/Book 2.89
Trade VIRX with:

Options Overview

Details
  • Implied Volatility 102.66%
  • Historical Volatility 64.31%
  • IV Percentile 14%
  • IV Rank 1.38%
  • IV High 179.38% on 03/11/21
  • IV Low 101.59% on 04/06/21
  • Put/Call Vol Ratio 1.00
  • Today's Volume 44
  • Volume Avg (30-Day) 95
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 6,373
  • Open Int (30-Day) 1,651

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -1.75
  • Growth Rate Est. (year over year) +92.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.61 +5.12%
on 03/19/21
10.06 -20.52%
on 04/01/21
-0.96 (-10.71%)
since 03/16/21
3-Month
7.61 +5.12%
on 03/19/21
24.80 -67.75%
on 02/24/21
-2.12 (-20.91%)
since 01/15/21
52-Week
3.92 +104.08%
on 11/06/20
24.80 -67.75%
on 02/24/21
-8.98 (-52.87%)
since 04/16/20

Most Recent Stories

More News
Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

, /PRNewswire/ --  Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20 Annual...

VIRX : 8.00 (-0.37%)
Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

and , /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), and XOMA Corporation (NASDAQ: XOMA) announced today XOMA has purchased the potential future milestones and royalties associated with existing...

VIRX : 8.00 (-0.37%)
XOMA : 37.50 (-0.92%)
Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

, /PRNewswire/ --  Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. , President and Chief Executive Officer of Viracta...

VIRX : 8.00 (-0.37%)
Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team

, /PRNewswire/ --  Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments...

VIRX : 8.00 (-0.37%)
Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

, /PRNewswire/ --  Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global...

VIRX : 8.00 (-0.37%)
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

, /PRNewswire/ -- Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc....

SNSS : 5.32 (+24.30%)
VIRX : 8.00 (-0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Viracta Therapeutics Inc. is a precision oncology company targeting virus-associated malignancies. The company is pursuing application of inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other virus-related cancers. Viracta...

See More

Key Turning Points

3rd Resistance Point 8.65
2nd Resistance Point 8.45
1st Resistance Point 8.22
Last Price 8.00
1st Support Level 7.79
2nd Support Level 7.59
3rd Support Level 7.36

See More

52-Week High 24.80
Fibonacci 61.8% 16.83
Fibonacci 50% 14.36
Fibonacci 38.2% 11.90
Last Price 8.00
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar